drugset
drugset / Trial / NCT06217952

Safety, Tolerability, and Pharmacokinetics of SPL84 in Healthy Volunteers

NCT06217952 ↗

Phase 1 Completed 32 enrolled SpliSense Ltd.
RandomizedSequentialDouble-blindTreatment

Summary

This Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of SPL84 single ascending doses (SAD) in healthy volunteers (HV)

Timeline

Start
2023-02-05
Primary completion
2023-08-06
Completion
2023-08-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator SPL84 Unknown — Other

Indications

cystic fibrosis